Celcuity Inc.: Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress

Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozoleMedian

Related Keywords

San Antonio ,Texas ,United States ,Germany ,Berlin ,Vicky Hahne ,Robert Uhl ,Brian Sullivan ,Igor Gorbatchevsky ,Twitter ,Linkedin ,Nasdaq ,Breast Cancer Congress See Table ,Breast Cancer Annual Congress ,European Society For Medical Oncology ,Exchange Commission On ,Celcuity Inc View ,Celcuity Inc ,Medical Oncology ,Escalation Arm ,Expansion Arm ,San Antonio Breast Cancer Symposium ,Chief Medical Officer ,Study Design ,Cancer Congress ,Measurable Disease ,Free Survival ,Full Analysis Set ,Breakthrough Therapy ,Risk Factors ,Annual Report ,Exchange Commission ,Gefallene Big Techs ,Celcuity ,Presents ,Pdated ,Results ,Rom ,Hase ,Study ,Gedatolisib ,Treatment ,A 239 Ve ,Patients ,023 ,Osmo ,Breast ,Dancer ,Nnual ,Congress ,